Cargando…
1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506388/ http://dx.doi.org/10.1016/j.annonc.2020.08.1574 |
| _version_ | 1783585007061696512 |
|---|---|
| author | Giaccone, G. Felip, E. Cobo, M. Campelo, R. Garcia DENIS, F. Quoix, E. Madroszyk, A. Debieuvre, D. Hilgers, W. Moran, T. Galetta, D. Romano, G.D. Cappuzzo, F. Robinet, G. Masson, P. Viteri, S. Peled, N. Costantini, D. Dziadziuszko, R. Besse, B. |
| author_facet | Giaccone, G. Felip, E. Cobo, M. Campelo, R. Garcia DENIS, F. Quoix, E. Madroszyk, A. Debieuvre, D. Hilgers, W. Moran, T. Galetta, D. Romano, G.D. Cappuzzo, F. Robinet, G. Masson, P. Viteri, S. Peled, N. Costantini, D. Dziadziuszko, R. Besse, B. |
| author_sort | Giaccone, G. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7506388 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75063882020-09-23 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial Giaccone, G. Felip, E. Cobo, M. Campelo, R. Garcia DENIS, F. Quoix, E. Madroszyk, A. Debieuvre, D. Hilgers, W. Moran, T. Galetta, D. Romano, G.D. Cappuzzo, F. Robinet, G. Masson, P. Viteri, S. Peled, N. Costantini, D. Dziadziuszko, R. Besse, B. Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2020-09 2020-09-22 /pmc/articles/PMC7506388/ http://dx.doi.org/10.1016/j.annonc.2020.08.1574 Text en Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Giaccone, G. Felip, E. Cobo, M. Campelo, R. Garcia DENIS, F. Quoix, E. Madroszyk, A. Debieuvre, D. Hilgers, W. Moran, T. Galetta, D. Romano, G.D. Cappuzzo, F. Robinet, G. Masson, P. Viteri, S. Peled, N. Costantini, D. Dziadziuszko, R. Besse, B. 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial |
| title | 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial |
| title_full | 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial |
| title_fullStr | 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial |
| title_full_unstemmed | 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial |
| title_short | 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial |
| title_sort | 1260mo activity of ose-2101 in hla-a2+ non-small cell lung cancer (nsclc) patients after failure to immune checkpoint inhibitors (ici): step 1 results of phase iii atalante-1 randomised trial |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506388/ http://dx.doi.org/10.1016/j.annonc.2020.08.1574 |
| work_keys_str_mv | AT giacconeg 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT felipe 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT cobom 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT campelorgarcia 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT denisf 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT quoixe 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT madroszyka 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT debieuvred 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT hilgersw 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT morant 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT galettad 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT romanogd 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT cappuzzof 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT robinetg 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT massonp 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT viteris 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT peledn 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT costantinid 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT dziadziuszkor 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial AT besseb 1260moactivityofose2101inhlaa2nonsmallcelllungcancernsclcpatientsafterfailuretoimmunecheckpointinhibitorsicistep1resultsofphaseiiiatalante1randomisedtrial |